Findings in the Area of Cholangiocarcinoma Reported from Massachusetts General Hospital (Egfr Inhibition Potentiates Fgfr Inhibitor Therapy and Overcomes Resistance In Fgfr2 Fusion-positive Cholangiocarcinoma)

MLA

“Findings in the Area of Cholangiocarcinoma Reported from Massachusetts General Hospital (Egfr Inhibition Potentiates Fgfr Inhibitor Therapy and Overcomes Resistance In Fgfr2 Fusion-Positive Cholangiocarcinoma).” Obesity, Fitness & Wellness Week, June 2022, p. 1870. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.706917326&authtype=sso&custid=ns315887.

APA

Findings in the Area of Cholangiocarcinoma Reported from Massachusetts General Hospital (Egfr Inhibition Potentiates Fgfr Inhibitor Therapy and Overcomes Resistance In Fgfr2 Fusion-positive Cholangiocarcinoma). (2022, June 18). Obesity, Fitness & Wellness Week, 1870.

Chicago

Obesity, Fitness & Wellness Week. 2022. “Findings in the Area of Cholangiocarcinoma Reported from Massachusetts General Hospital (Egfr Inhibition Potentiates Fgfr Inhibitor Therapy and Overcomes Resistance In Fgfr2 Fusion-Positive Cholangiocarcinoma),” June 18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.706917326&authtype=sso&custid=ns315887.